Numab Therapeutics AG logo

Numab Therapeutics AG

Numab is a Swiss biotech company that innovates antibody-based therapeutics. Numabs strength is the engineering of molecules with tailored pharmacological properties (e.g. multi-specific products with short or long half-life).

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.numab.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Churerstrasse 80 CH-8808
Pfaffikon
Switzerland
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/numab-ag” connections=”true” suffix=””]

Numabs proprietary antibody discovery and engineering technology, generates highly potent and stable antibody Fv fragments, which serve as building blocks to create mono- or multispecific antibody fragment-based therapeutics with tailored pharmacokinetic properties.

In Mar 2017, Numab signed R&D agreement with Ono Pharmaceutical for the identification and development of a multi-specific immuno-oncology antibody candidate. Under the terms, Ono will obtain an option to acquire exclusive rights to develop and commercialize, the selected lead compound generated through this collaboration, which will exploit one of Onos novel therapeutic approaches in immuno-oncology. In exchange Numab will receive research funding and up to CHF 258 Mn in upfront and milestone payments plus tiered single to double digit royalties on sales.